Actelion Share Price CBOE EUROPE EQUITIES

Stocks

End-of-day quote CBOE EUROPE EQUITIES Other stock markets
- ^CHF	-

31/17/31	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
19/17/19	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE

31/17/31	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
19/17/19	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
19/17/19	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
09/17/09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/17/09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/17/09	Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	RE
22/17/22	Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	RE
18/17/18	Actelion : Johnson & Johnson offers EU concessions over Actelion deal	RE
20/17/20	Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	RE
18/17/18	Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	RE
05/17/05	Actelion : shareholders back R&D spinoff, keep J&J deal on track	RE
31/17/31	Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	RE
23/17/23	Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	RE

06/20/06	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
31/17/31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
30/17/30	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
16/17/16	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
16/17/16	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU

29/18/29	Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
29/18/29	Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
22/18/22	Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
31/17/31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
30/17/30	Actelion: la décotation est agendée au 7 novembre

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+8.49%	+20.55%	+69.74%	+109.30%	6.81TCr
ARGENX SE	+1.25%	+2.44%	+32.55%	+72.63%	5.52TCr
INSMED INCORPORATED	-1.09%	+32.96%	+19.95%	+499.45%	2.86TCr
BIONTECH SE	+2.72%	+3.41%	-15.88%	-4.90%	2.35TCr
WUXI BIOLOGICS (CAYMAN) INC.	+10.83%	+18.38%	+52.76%	+4.58%	2.4TCr
GENMAB A/S	+6.50%	+7.56%	+38.20%	-21.33%	1.84TCr
PHARMAESSENTIA CORPORATION	-3.88%	+16.98%	+199.30%	+354.30%	1.58TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.20%	+11.51%	+34.94%	+681.88%	1.64TCr
EXELIXIS, INC.	+3.58%	+1.96%	+44.61%	+167.01%	1.34TCr
Average	+3.84%	+11.68%	+52.91%	+206.99%	2.93TCr
Weighted average by Cap.	+4.36%	+13.10%	+49.48%	+168.49%